Clinical trials: Meningococcal
Vaccination
A Phase IV Study to Evaluate the Immunogenicity and Safety in UK Laboratory Workers of Menitorix
Menitorix is a combined Hib conjugate and meningococcal C conjugate vaccine made by GlaxoSmithKline. It is currently licensed and recommended as a booster vaccination for UK children in the second year of life.
- Trial name
- NCT00503165
- Testing
- Menitorix (MenC and Hib conjugate)
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Public Health England
Meningococcal Meningitis
Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.
To compare the functional immune response 28 days after administration of one dose of Men ACWY-CRM conjugate vaccine without adjuvant (MenACWY-CRM(Ad-)) with that of a Men ACWY polysaccharide (PS) vaccine
- Trial name
- NCT00310817
- Testing
- MenACWY-CRM conjugate vaccine, adjuvanted, MenACWY polysaccharide vaccine, MenACWY-CRM conjugate vaccine, unadjuvanted
- Where
- 2 sites in Finland, Poland
- Volunteers
- 623 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningitis, Meningococcal Infection
Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®
The study is designed to evaluate the persistence of bactericidal antibodies in subjects aged 15 to 23 years (not yet 24 years) who had been vaccinated five years previously in Study MTA02 and did not participate in Study MTA19…
- Trial name
- NCT00269477
- Testing
- Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- Where
- 8 sites in United States
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Bacterial Meningitis
Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 18 Years in Taiwan
This study will evaluate the immunogenicity and safety of a single injection of Novartis Meningococcal ACWY conjugate vaccine in healthy subjects from 2 to 18 years in Taiwan.
- Trial name
- NCT01410474
- Testing
- Meningococcal ACWY conjugate vaccine
- Where
- 3 sites in China
- Volunteers
- 341 people, healthy volunteers welcome
- Sponsor
- Novartis
Meningococcal Infection
Immunogenicity of the Booster Dose of Two MenC Vaccines
The purpose of the study is to evaluate the immune response of toddlers, to a booster dose in the second year of life of two meningococcal C conjugated polysaccharide vaccine, and to assess the interchangeability of the two…
- Trial name
- CSISP-MENC1 (NCT00392808)
- Testing
- conjugated polysaccharide menC vaccine
- Where
- 2 sites in Spain
- Volunteers
- 389 people, healthy volunteers welcome
- Sponsor
- Centro Superior de Investigación en Salud Publica
Meningitis
Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 001
The clinical trial was designed to evaluate the safety against Group ACYW135 Meningococcal Polysaccharide Vaccine of Hualan administered on subjects 2 years of age and older.
- Trial name
- NCT01661725
- Testing
- Group ACYW135 Meningococcal Polysaccharide Vaccine
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hualan Biological Engineering, Inc.
Meningitis, Meningococcal
Ciprofloxacin for the Prevention of Meningococcal Meningitis
This study evaluates the effect of antibiotic prophylaxis with ciprofloxacin, given to the contacts of meningitis cases, on the overall attack rate of meningitis during an epidemic.
- Trial name
- NCT02724046
- Testing
- Ciprofloxacin
- Where
- Niger
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Epicentre
Meningococcal Meningitis
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
The primary objective is to evaluate the persistence of bactericidal antibodies in adolescents previously enrolled in the V59P13 study who received either Novartis MenACWY Conjugate Vaccine or commercially available MenACWY…
- Trial name
- NCT00856297
- Testing
- MenACWY-CRM conjugate vaccine, Licensed comparator
- Where
- 32 sites in United States
- Volunteers
- 389 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Group A, C Polysaccharide Meningitis, Type b Haemophilus Influenza
Immunogenicity and Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Infants and Children
Haemophilus influenzae is an important pathogen which can cause primary infection and respiratory viral infection in infants and leaded to secondary infections.
- Trial name
- NCT01428908
- Testing
- A+C+hib Conjugate Vaccine, A+C Vaccine, Hib vaccine
- Where
- China
- Volunteers
- 2,394 people
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Meningitis, Meningococcal
A Study Assessing Colonisation & Immunogenicity After Nasal Inoculation With N. Lactamica and Eradication on Day 4 or 14
This study is part of a project that aims to develop a vaccine with N. lactamica that prevents meningitis. The investigators have previously given nose drops containing N.
- Trial name
- Lac-3 (NCT03549325)
- Testing
- Neisseria lactamica
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Relapsing Forms of Multiple Sclerosis
Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
Primary objective is to evaluate the immune response to vaccination with tetanus diphtheria toxoids vaccine (Td) in participants with relapsing forms of Multiple Sclerosis (MS) who have been treated with Tecfidera (BG00012)…
- Trial name
- NCT02097849
- Testing
- dimethyl fumarate, tetanus diphtheria toxoids vaccine, 23-valent pneumococcal polysaccharide vaccine
- Where
- 14 sites in United States
- Volunteers
- 71 people
- Sponsor
- Biogen
Vaccine Preventable Diseases, Meningococcal Disease
Testing the Use of Prompts to Increase Adolescent Immunization Rates
Although most US adolescents visit their primary care doctor, their immunization rates are low. Primary care practices from two networks, one in upstate New York as well as a national network of pediatric clinics were surveyed to…
- Conditions
- Vaccine Preventable Diseases, Meningococcal Disease, Human Papillomavirus, Pertussis
- Trial name
- AIMHi (NCT01984125)
- Testing
- Point-of-Care Prompt
- Where
- 22 sites in United States
- Volunteers
- 7,040 people
- Sponsor
- University of California, Los Angeles
Meningococcal Disease, Meningococcal Meningitis
Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine
This study compares the safety and immunogenicity profile of combined hepatitis A/B vaccine given alone or concomitantly with MenACWY-CRM to healthy adults.
- Conditions
- Meningococcal Disease, Meningococcal Meningitis, Hepatitis A, Hepatitis B
- Trial name
- NCT01453348
- Testing
- MenACWY-CRM, Combined inactivated hepatitis A & recombinant hepatitis B, Recombinant hepatitis B vaccine
- Where
- 4 sites in Germany
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningococcal Disease, Meningococcal Meningitis
Immunogenicity and Safety of Different rMenB Plus MenACWY Formulations in Adolescents
The purpose of this phase 2 study is to evaluate the safety, tolerability and immunogenicity of two doses of 4 different investigational MenABCWY combination vaccine when administered to healthy adolescents aged 11-18 years.
- Trial name
- NCT01210885
- Testing
- Meningococcal Vaccine
- Where
- 8 sites in Chile, Colombia and 1 more
- Volunteers
- 495 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Bacterial Sepsis
Detoxified J5 Core Glycolipid/ Group B Meningococcal Outer Membrane Protein Vaccine for Gram-negative Bacterial Sepsis Administered With and Without Synthetic CPG Oligodeoxynucleotide 7909 Adjuvant
The purpose of this study is to test the safety of an experimental vaccine against sepsis (infection of the blood) alone and with an experimental adjuvant (a substance that may improve vaccine effectiveness).
- Trial name
- NCT01164514
- Testing
- CPG 7909, J5-OMP Vaccine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Meningococcal Serogroup B
Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults
The overall aim of this study is to determine if an accelerated "Bexsero® (Multicomponent meningococcal B vaccine)" schedule compared to a standard schedule is immunogenic, safe, and tolerable, in order to increase capacity for…
- Trial name
- NCT02583412
- Testing
- Bexsero®, Havrix®
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Canadian Immunization Research Network
Epidemic Meningitis, Meningococcal Vaccines
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months
The goal of this clinical trial is to evaluate the immunogenicity and safety of an investigational group ACYW135 Meningococcal conjugate vaccine in healthy children aged 12 to 23 months.
- Trial name
- NCT07505836
- Testing
- experimental vaccine, Active Comparator vaccine
- Where
- 2 sites in China
- Volunteers
- 1,040 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Preventive Immunization; Meningitis
Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in Frequent Platelets Donors
In this study, the investigators will evaluate the immunogenicity of a quadrivalent conjugate meningococcal vaccine in healthy, plateletpheresis donors.
- Trial name
- PLAT (NCT04224311)
- Testing
- Menactra
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Meningococcal Disease
B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants
This study is aimed to assess whether the frequency of meningococcal serogroup A, C, W-135 and Y specific memory B Cells, measured 1 month after a primary vaccination series of Novartis MenACWY vaccine, predicts the specific…
- Trial name
- NCT00488683
- Testing
- MenACWY-CRM, DTaP-Hib-IPV, PCV
- Where
- United Kingdom
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Meningococcal Disease
Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines
Invasive meningococcal disease is a worldwide problem with serious repercussions for those affected. Vaccination is recognized as the best way to combat it.
- Trial name
- NCT01782066
- Testing
- MEN-ACYW135 reduced-dose intradermal administration
- Where
- Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center